Hematology
Volume 27, 2022 - Issue 1
Open access
5,066
Views
5
CrossRef citations to date
0
Altmetric
Rapid Communication
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
Faouzi Djebbaria Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKCorrespondence[email protected]
https://orcid.org/0000-0001-9578-7632
Matt Poyntonb Royal Berkshire Hospital, Reading, UK
, Gina Sanghac Milton Keynes Hospital, Milton Keynes, UK
, Laura Andersond Royal United Hospital Bath, Bath, UK
, Rebecca Maddamse Poole Hospital, Poole, UK
, Toby A. Eyrea Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
, Grant Vallancea Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
, Supratik Basuf The Royal Wolverhampton NHS Trust, Wolverhampton, UK;g Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK;h West Midlands Research Consortium (WMRC), West Midlands, UK
& Karthik Ramasamya Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
show all
Pages 204-207
|
Published online: 08 Feb 2022
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.